Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T20:33:24.888Z.
Calculation as of: 2026-10-06T20:33:24.888Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0a7bb93a2e834ec7067e9d54c2948749c38dd5402669cdea4977ff55dc99d60c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Valion Bio, Inc.
Market Cap
$9.86M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Valion Bio, Inc. (VBIO) | $9.86M | N/A |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.83M | N/A |
| MetaVia Inc. (MTVA)vs › | $9.75M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.06M | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.13M | N/A |
| Ainos, Inc. (AIMD)vs › | $9.50M | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.21M | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
